Nilay Shah
@nilaydshah1
health services researcher with a focus on improving chronic care for complex patients and issues related to pharmaceutical policy; On Wisconsin!
ID:247186058
04-02-2011 08:06:20
1,6K Tweets
473 Followers
1,4K Following
Follow People
TWEETORIAL ALERT💵
In this NEJM perspective, Stacie Dusetzina David D. Kim (김대호) Ashley Leech and I write about the costs and questions around new use of antiobesity medications (AOMs) like #Wegovy #semaglutide in the #Medicare #PartD program if #TROA passes.
1/12
nejm.org/doi/full/10.10…
Wherein Sam Burn Timothy Layton Boris Vabson and I take on the unenviable task of defending medical paperwork:
'Rationing Medicine Through Bureaucracy: Authorization Restrictions in Medicare'
on NBER: nber.org/papers/w30878
and ungated: zarekcb.github.io/PriorAuth_Web.…
1/ Super excited about the new primary care model we’ve been working on Carbon Health and have launched in Mass. with Blue Cross MA.
Our model brings together things I’ve been dreaming about since exploring primary care at Apple.
We call it Connective Care, and it’s here now. 🧵
Many top nonprofit hospital systems avoid communities where more people are likely to need aid. “We have a healthcare desert.” wsj.com/articles/nonpr… via The Wall Street Journal
Less than a third of regulatory actions taken by the US Food and Drug Administration (FDA) are corroborated by published research findings or public assessments, finds new research bmj.com/content/379/bm… Reshma Ramachandran Joseph Ross Joshua D. Wallach Xiaoting Shi Meera Dhodapkar
In this emulation of the GRADE trial, liraglutide was statistically significantly more effective at maintaining glycemic control than glimepiride or sitagliptin when added to metformin monotherapy, find Rozalina (Grubina) McCoy, MD MS and colleagues
bmj.com/content/379/bm…
We are seeing multiple variants with convergent evolution that will drive the next wave.
All variants with 5+ key RBD mutations can be grouped together, I am referring to this group as 'Pentagon' for sharing the 5 mutations.
Thank you Cornelius Roemer for covspectrum collection
Surprise? Per Milliman, Inc., #Medicare #PartD plans prefer brand-name long-acting #insulins over Semglee #biosimilar . I think we all know why...
#PBM #DIR #GrossToNetBubble #rebates
P.S Study funded by PCMA (!)
drugch.nl/3xEOtxf
Thoughtful piece by (((Howard Forman))), Jennifer E. Miller & Long Tu on how the contrast shortage should spur changes in medicolegal environment and culture of medicine to support provision of high-value care, making health care more sensible, affordable, and fairer nejm.org/doi/full/10.10…